Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

• US 7,470,663 B2
• Filed: 05/04/2006
• Issued: 12/30/2008
• Est. Priority Date: 06/04/2001
• Status: Expired due to Fees

• Current Assignee: Biocon Limited (Biocon Incorporated)
• Original Assignee: Biocon Limited (Biocon Incorporated)
• Inventors: Radhakrishnan, Balasingam, Ekwuribe, Nnochiri N., Odenbaugh, Amy L., Price, Christopher H., Ansari, Aslam M.
• Primary Examiner(s): Russel; Jeffrey E
• Application Number:
  US11/417,586
• Publication Number:
  US 20060199759A1
• Time in Patent Office: 971 Days
• Field of Search: None
• US Class Current: 514/1.1
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin

Abstract

A mixture of conjugates in which each conjugate in the mixture comprises an insulin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugates. The mixture may also be more effective at surviving an in vitro model of intestinal digestion than polydispersed mixtures of similar conjugates. The mixture may also result in less inter-subject variability than polydispersed mixtures of similar conjugates.

Claims

1. A liquid solution formulated for oral delivery in a subject comprising a substantially monodispersed mixture of conjugates, wherein each conjugate comprises human insulin covalently coupled at Lys^B29 of the human insulin to the carboxylic acid moiety of a carboxylic acid, which is covalently coupled at the end distal to the carboxylic acid moiety to a methyl terminated polyethylene glycol moiety having 7 polyethylene glycol subunits, wherein said mixture has a molecular weight distribution with a standard deviation of less than about 22 Daltons.

2. A liquid solution formulated for oral delivery in a subject comprising a substantially monodispersed mixture of conjugates, wherein each conjugate comprises human insulin covalently coupled at Lys^B29 of the human insulin to the carboxylic acid moiety of a carboxylic acid, which is covalently coupled at the end distal to the carboxylic acid moiety to a methyl terminated polyethylene glycol moiety having a number of polyethylene glycol subunits selected from the group consisting of 4 units, 7 units and 10 units, wherein said mixture has a molecular weight distribution with a standard deviation of less than about 22 Daltons wherein the conjugates are suspended in an aqueous or non-aqueous solution, said mixture having an in vivo activity that is greater than the in vivo activity of a polydispersed mixture of insulin drug-oligomer conjugates having the same number average molecular weight as the substantially monodispersed mixture.

3. The liquid solution according to claim 2, further having an in vitro activity that is greater than the in vitro activity of the polydispersed mixture of insulin-oligomer conjugates.

4. The liquid solution according to claim 2, further having an increased resistance to degradation by chymotrypsin when compared to the resistance to degradation by chymotrypsin of the polydispersed mixture of insulin-oligomer conjugates.

5. The liquid solution according to claim 2, further having an inter-subject variability that is less than the inter-subject variability of the polydispersed mixture of insulin-oligomer conjugates.